# US 2026/0061045 A1 · Method for prevention and treatment of viral disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061045 A1
- Document ID: US20260061045A1
- Status: Published application
- Kind: A1
- Application number: 19/320,827
- Filed: 2025-09-05
- Published: 2026-03-05
- Earliest claimed: 2024-07-29
- Assignees: Morehouse School of Medicine
- Applicants: Morehouse School of Medicine
- Inventors: Barney S. GRAHAM; Erica L. JOHNSON; James W. LILLARD
- Web page: https://patentgrep.com/patent/US20260061045A1

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/12: Viral antigens
- A61P 31/16: for influenza or rhinoviruses
- A61P 37/04: Immunostimulants
- C07K 14/005: from viruses
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12Y 302/01018: Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/543: {intranasal}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- A61K 2039/6031: {Proteins}
- A61K 2039/70: {Multivalent vaccine}
- C07K 2319/00: Fusion polypeptide
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16171: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method for reducing mortality resulting from viral infection, reducing viral load resulting from viral infection, or increasing immunity to viral infection in a subject is described. The method comprises administering a hybrid protein comprises a first domain comprising a sequence encoding a surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain. The hybrid protein or an mRNA encoding such protein can be used as a vaccine against the infection of the enveloped RNA virus.

## Claims

### Claim 1

A method for reducing mortality resulting from viral infection comprising:
administering to a subject in need thereof an effective amount of a composition comprising a hybrid protein comprising a first domain comprising a sequence encoding an ectodomain of a trimeric surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain; and
a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The method of claim 1, wherein the viral infection is an influenza infection.

### Claim 3 (depends on 1)

The method of claim 1, wherein the enveloped RNA virus is H1N1, H1N3, H3N2, H3N8, H5N1, H5N6, H7N9, or an influenza B virus.

### Claim 4 (depends on 1)

The method of claim 1, wherein the surface protein is a mutated hemagglutinin (HA), wherein the second domain comprises an ectodomain of a neuraminidase (NA), wherein the mutated HA comprises a mutation that reduces aggregation and non-specific binding to sialic acid.

### Claim 5 (depends on 4)

The method of claim 4, wherein a furin cleavage site of mutated HA is replaced with a linker sequence.

### Claim 6 (depends on 1)

The method of claim 1, wherein the hybrid protein comprises SEQ ID NO:13.

### Claim 7 (depends on 1)

The method of claim 1, wherein the hybrid protein comprises a sequence selected from the group consisting of SEQ ID NOS: 24-27.

### Claim 8

A method for reducing viral load resulting from a viral infection in a subject in need thereof, comprising:
administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising a hybrid protein comprising a first domain comprising a sequence encoding an ectodomain of a trimeric surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain; and
a pharmaceutically acceptable carrier.

### Claim 9 (depends on 8)

The method of claim 8, wherein the viral infection is an influenza infection.

### Claim 10 (depends on 8)

The method of claim 8, wherein the enveloped RNA virus is H1N1, H1N3, H3N2, H3N8, H5N1, H5N6, H7N9, or an influenza B virus.

### Claim 11 (depends on 8)

The method of claim 8, wherein the surface protein is a mutated hemagglutinin (HA), wherein the second domain comprises an ectodomain of a neuraminidase (NA), wherein the mutated HA comprises a mutation that reduces aggregation and non-specific binding to sialic acid.

### Claim 12 (depends on 11)

The method of claim 11, wherein a furin cleavage site of mutated HA is replaced with a linker sequence.

### Claim 13 (depends on 8)

The method of claim 8, wherein the hybrid protein comprises SEQ ID NO:13.

### Claim 14 (depends on 8)

The method of claim 8, wherein the hybrid protein comprises a sequence selected from the group consisting of SEQ ID NOS: 24-27.

### Claim 15

A method for increasing immunity to viral infection in a subject in need thereof, comprising:
administering to the subject in need thereof an effective amount of a pharmaceutical composition comprising a hybrid protein comprising a first domain comprising a sequence encoding an ectodomain of a trimeric surface protein of an enveloped RNA virus and a second domain comprising a sequence encoding an ectodomain of a type 2 transmembrane domain protein, wherein the second domain is located at the C-terminal of the first domain; and
a pharmaceutically acceptable carrier.

### Claim 16 (depends on 15)

The method of claim 15, wherein the viral infection is an influenza infection.

### Claim 17 (depends on 15)

The method of claim 15, wherein the enveloped RNA virus is H1N1, H1N3, H3N2, H3N8, H5N1, H5N6, H7N9, or an influenza B virus.

### Claim 18 (depends on 15)

The method of claim 15, wherein the surface protein is a mutated hemagglutinin (HA), wherein the second domain comprises an ectodomain of a neuraminidase (NA), wherein the mutated HA comprises a mutation that reduces aggregation and non-specific binding to sialic acid.

### Claim 19 (depends on 18)

The method of claim 18, wherein a furin cleavage site of mutated HA is replaced with a linker sequence.

### Claim 20 (depends on 15)

The method of claim 15, wherein the hybrid protein comprises a sequence selected from the group consisting of SEQ ID NOS: 13 and 24-27.
